Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

324
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
324
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

948
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
948
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

786
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
786
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.2K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.2K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

315
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
315

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Simultaneous Mastopexy-Augmentation for Small Ptotic Breasts: A Literature Review.

Annals of plastic surgery·2026
Same author

Expanding Horizons: The Vanderbilt Plastic Surgery Annual Lecture Series.

Annals of plastic surgery·2026
Same author

Cutaneous Injuries From an Nd:YAG Laser Directed-Energy Source Utilizing a Murine Model: A Pilot Study for Establishing a Laser Burn Murine Model.

Annals of plastic surgery·2026
Same author

Safety Profile of Facial Cosmetic Surgery Under Local Anesthesia, with or without Sedation: A Systematic Review and Meta-analysis.

Aesthetic plastic surgery·2026
Same author

Vascular Anomalies: A Comprehensive Review of Etiology, Complications, and Management Strategies.

Annals of plastic surgery·2026
Same author

Experimental Rat Peripheral Nerve Models: Surgical Exposures and Applications.

Annals of plastic surgery·2026

Related Experiment Video

Updated: Feb 28, 2026

Sleeve Gastrectomy in Mice using Surgical Clips
05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

7.5K

Post-weight Loss Body Contouring Surgery: Complication Rates Following Bariatric Surgery, Injectable GLP-1

Erin N Abbott1, Emmanuel Giannas1, Nomongo Dorjsuren2

  • 1Department of Plastic Surgery, Vanderbilt University Medical Center, Nashville, TN.

Aesthetic Surgery Journal
|February 26, 2026
PubMed
Summary
This summary is machine-generated.

Weight loss method does not affect body contouring surgery complications. Higher BMI and diabetes are key risk factors for adverse outcomes in post-weight loss patients.

More Related Videos

Roux-en-Y Gastric Bypass Operation in Rats
07:37

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

24.4K
Techniques of Sleeve Gastrectomy and Modified Roux-en-Y Gastric Bypass in Mice
10:05

Techniques of Sleeve Gastrectomy and Modified Roux-en-Y Gastric Bypass in Mice

Published on: March 20, 2017

12.8K

Related Experiment Videos

Last Updated: Feb 28, 2026

Sleeve Gastrectomy in Mice using Surgical Clips
05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

7.5K
Roux-en-Y Gastric Bypass Operation in Rats
07:37

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

24.4K
Techniques of Sleeve Gastrectomy and Modified Roux-en-Y Gastric Bypass in Mice
10:05

Techniques of Sleeve Gastrectomy and Modified Roux-en-Y Gastric Bypass in Mice

Published on: March 20, 2017

12.8K

Area of Science:

  • Plastic Surgery
  • Bariatric Medicine
  • Metabolic Health

Background:

  • Rising demand for body contouring post-weight loss, particularly with Glucagon-like Peptide-1 receptor agonists (GLP-1 RA).
  • Uncertainty regarding the influence of various weight-loss strategies on surgical outcomes.
  • Need for clarity on patient selection and operative considerations.

Purpose of the Study:

  • Compare complication rates among different weight loss modalities.
  • Identify predictors of adverse outcomes in patients undergoing body contouring surgery.
  • Evaluate the impact of weight loss methods on post-operative results.

Main Methods:

  • Retrospective cohort study of 1,002 patients undergoing body contouring after weight loss (Jan 2019-Dec 2024).
  • Classification into four weight loss groups: surgical, GLP-1 pharmacotherapy, combination, and lifestyle.
  • Analysis of postoperative complications within 90 days for panniculectomy, brachioplasty, thighplasty, and breast procedures.

Main Results:

  • Weight loss methods included surgery (67.9%), lifestyle (14.3%), GLP-1 pharmacotherapy (7.8%), and combination (10.1%).
  • No significant difference in overall complication rates across weight loss modalities.
  • Higher BMI and presence of diabetes independently predicted increased risk of complications.

Conclusions:

  • Weight loss modality does not influence postoperative complication incidence in body contouring.
  • Body Mass Index (BMI) at surgery and diabetes are significant predictors of adverse outcomes.
  • Focus on patient-specific risk factors like BMI and diabetes is crucial for optimizing surgical outcomes.